Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.

Current treatment of Parkinson's disease (PD) is based on dopamine replacement therapy, but this leads to long term complications, including dyskinesia. Adenosine A2A receptors are particularly abundant in the striatum and would be a target for an alternative approach to the treatment of PD.
The purpose of this study is to examine the efficacy and potency of the novel selective adenosine A2A receptor antagonist (E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dhydro- 1H-purine-2,6- dione (KW-6002) in ameliorating the motor deficits in various mouse models of Parkinson's disease.
We evaluated the efficacy and potency of KW-6002 and other reference compounds in the selective adenosine A2A receptor agonist 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosin e (CGS 21680)-, haloperidol- or reserpine-induced catalepsy models. The effect of KW-6002 on reserpine or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride(MPTP)-induced hypolocomotion was also examined.
The ED50s of KW-6002 in the reversal of CGS21680-induced and reserpine-induced catalepsy were 0.05 mg/kg, PO and 0.26 mg/kg, PO, respectively. Compared to the ED50 of other adenosine antagonists and dopamine agonist drugs, KW-6002 is over 10 times as potent in these models. KW-6002 also ameliorated the hypolocomotion (minimum effective dose; 0.16 mg/kg) induced by nigral dopaminergic dysfunction with MPTP or reserpine treatment. Combined administrations of subthreshold doses of KW-6002 and L-dopa (50 mg/kg, PO) exerted prominent effects on haloperidol-induced and reserpine-induced catalepsy, suggesting that there may be a synergism between the adenosine A2A receptor antagonist KW-6002 and dopaminergic agents.
To our knowledge, KW-6002 is the most potent and orally active adenosine A2A receptor antagonist in experimental models of Parkinson's disease, and may offer a new therapeutic approach to the treatment of Parkinson's disease.
AuthorsS Shiozaki, S Ichikawa, J Nakamura, S Kitamura, K Yamada, Y Kuwana
JournalPsychopharmacology (Psychopharmacology (Berl)) Vol. 147 Issue 1 Pg. 90-5 (Nov 1999) ISSN: 0033-3158 [Print] GERMANY
PMID10591873 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiparkinson Agents
  • Antipsychotic Agents
  • Dopamine Agents
  • Phenethylamines
  • Phosphodiesterase Inhibitors
  • Purinergic P1 Receptor Agonists
  • Purinergic P1 Receptor Antagonists
  • Purines
  • 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
  • istradefylline
  • Caffeine
  • Levodopa
  • Reserpine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Theophylline
  • Adenosine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (antagonists & inhibitors, pharmacology)
  • Adenosine (analogs & derivatives, pharmacology)
  • Animals
  • Antiparkinson Agents (pharmacology)
  • Antipsychotic Agents (antagonists & inhibitors, pharmacology)
  • Caffeine (pharmacology)
  • Catalepsy (chemically induced, prevention & control)
  • Dopamine Agents (pharmacology)
  • Hypokinesia (chemically induced, prevention & control)
  • Levodopa (pharmacology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Motor Activity (drug effects)
  • Phenethylamines (pharmacology)
  • Phosphodiesterase Inhibitors (pharmacology)
  • Purinergic P1 Receptor Agonists
  • Purinergic P1 Receptor Antagonists
  • Purines (pharmacology)
  • Reserpine (antagonists & inhibitors, pharmacology)
  • Theophylline (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: